WO2001018735A2 - Apparatus and methods for drug analysis and development - Google Patents
Apparatus and methods for drug analysis and development Download PDFInfo
- Publication number
- WO2001018735A2 WO2001018735A2 PCT/US2000/024781 US0024781W WO0118735A2 WO 2001018735 A2 WO2001018735 A2 WO 2001018735A2 US 0024781 W US0024781 W US 0024781W WO 0118735 A2 WO0118735 A2 WO 0118735A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- routine
- drug
- leukocyte response
- data
- leukocyte
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Definitions
- the present invention relates to apparatus and methods for drug analysis and development.
- the present invention provides methods for providing a database that contains data describing effects of agents on leukocyte activation, and provides methods and apparatus for extracting information from the database for drug analysis and development.
- Willmann describes methods for performing such measurements by combining a sample of whole blood with LPS in the presence of brefeldin A, and then surface-staining the cells in the sample with dendritic cell-distinguishing, fluorophore-conjugated antibodies. After removing red blood cells from the sample, the sample is further stained using antibodies labeled with flow cytometrically distinguishable fluorophores that bind specifically to cell surface activation markers and intracellular cytokines. Finally, the cells are analyzed by flow cytometry to determine the quantity of cell surface activation markers and intracellular cytokines present in the sample. Willmann also describes advantages of using such methods to monitor the effect of drugs on dendritic cell activation.
- leukocyte response data i.e., data that describes the effect of a particular concentration of a particular drug on the activation of a particular leukocyte cell type for a particular donor.
- leukocyte response data may include a donor identification (e.g., name or identifying number), the drug name (e.g., cyclosporin A), the drug concentration (e.g., 25 ⁇ M) , the particular leukocyte cell type that is tested (e.g., monocytes) , the activator that is mixed with the whole blood (e.g., LPS), the activation marker that is monitored (e.g., TNF ⁇ ), the relative change in activation in the population as a whole (e.g., 170% — i.e., a 70% enhancement of TNF ⁇ expression compared to whole blood that has not been combined with cyclosporin A) , or a change that is nonuniform among the cells of the tested population, revealing a previously unresolved drug-responsive or drug-resistant subpopulation of leukocytes.
- a donor identification e.g., name or identifying number
- the drug name e.g., cyclosporin A
- the drug concentration
- leukocyte response data By performing many tests on many different samples, a large quantity of leukocyte response data may be generated. Such leukocyte response data, however, have not previously been combined to quantitatively describe the immune function response when whole blood is exposed to drugs. Moreover, such data has not been combined in a manner that facilitates the analysis of the immune system when whole blood is exposed to drugs.
- leukocyte response data obtained from whole blood flow cytometry assays.
- a server computer may store leukocyte response data in a leukocyte response database, and users may interact with the server computer over an Intranet or the Internet.
- a user may communicate with the system using a standard web browser, and may extract and display data from the database in the web browser.
- the leukocyte response database may contain data provided by one or more researchers working within a single entity (e.g., a single corporation, research laboratory, or university) , or may be collaboratively provided by many researchers working at many different locations throughout the world (e.g., many corporations, laboratories and universities) . By combining validated data from multiple sources, data in the leukocyte response database may be continually updated and expanded to reflect the latest research.
- a single entity e.g., a single corporation, research laboratory, or university
- data in the leukocyte response database may be continually updated and expanded to reflect the latest research.
- FIG. 1 shows a database construction stage of the present invention
- FIG. 2 shows an illustrative database record in accordance with chis invention
- FIG. 3 shows an illustrative data extraction process in accordance with this invention
- FIGS. 4A and 4B show illustrative displays of results of a data extraction process in accordance with this invention
- FIG. 5 shows another illustrative data extraction process in accordance with this invention
- FIG. 6 shows another illustrative database record in accordance with this invention.
- FIG. 7 shows another illustrative data extraction process in accordance with this invention.
- FIG. 8 shows another illustrative display of results of a data extraction process in accordance with this invention.
- FIG. 9 shows another illustrative data extraction process in accordance with this invention
- FIG. 10 shows another illustrative data extraction process in accordance with this invention
- FIG. 11 shows another illustrative display of results of a data extraction process in accordance with this invention.
- FIG. 12 shows an illustrative computer network on which the database and methods of the present invention may be implemented.
- This invention provides a system for storing leukocyte response data in a database and for extracting data from the database.
- the system comprises a database construction stage, in which leukocyte response data are collected and stored in a leukocyte response database, and a data analysis stage that may be used to analyze data in the database.
- a database is a compilation of data stored on a computer system, such as in computer memory.
- a database may contain records, organized into one or more fields that each identify a specific data type (e.g., leukocyte cell type, leukocyte activators, etc.).
- a record comprises data populating each of the fields associated with the record, although some fields may have null values.
- FIG. 1 an illustrative database construction stage of a system of this invention is described. In this stage, leukocyte response data are collected to create a leukocyte response database.
- Leukocyte response data 10 may be generated by researchers at a single institution, such as a single pharmaceutical company or university, or may be generated by researchers from many different institutions.
- data 10 may be provided by a wide variety of sources, it may be desirable to screen the data before including it in leukocyte response database 16.
- data 10 may be provided to a scientific review board, which reviews data at step 12 (e.g., for scientific validity) to determine whether the data should be included in leukocyte response database 16.
- step 14 data that has been reviewed is checked to see if it meets predetermined inclusion criteria (e.g., covers leukocyte response data of interest to a particular user community) and should be included in database 16. If the data meets the inclusion criteria, the data are stored in database 16. If the data do not meet the inclusion criteria, the data are not included in database 16, and the review of the data may be archived at step 18.
- predetermined inclusion criteria e.g., covers leukocyte response data of interest to a particular user community
- Leukocyte response data are stored in database 16 in leukocyte response records. Referring to FIG. 2, an illustrative leukocyte response record is described. Leukocyte response record 20 contains six data fields: 22, 24, 26, 28, 30 and 32. Field 22 specifies the drug name (e.g., cyclosporin A), and field 24 describes the drug concentration (e.g., 25 ⁇ M) .
- drug name e.g., cyclosporin A
- field 24 describes the drug concentration (e.g., 25 ⁇ M) .
- Field 26 specifies leukocyte cell type (e.g., B-cells, T-cells, monocytes, etc.), field 28 describes the cell activators used to activate that cell type (e.g., LPS, CD40 and IL-4, SEB, CD28 and CD49d, etc.), and field 30 describes the activation markers examined (e.g., Il-l ⁇ , CD25, CD69, etc.).
- Field 32 describes the response of the leukocyte to the drug (e.g., expression of IL-l ⁇ in a sample containing 25 ⁇ M cyclosporin A was 115% of the expression in a sample containing no drug) .
- the drug e.g., expression of IL-l ⁇ in a sample containing 25 ⁇ M cyclosporin A was 115% of the expression in a sample containing no drug.
- Database 16 preferably will be populated with many records for many different leukocyte cell types, tested with many different concentrations of many different drugs.
- database 16 preferably will be populated with records having leukocyte response data from many individual blood donors. Once sufficient leukocyte response data are available in leukocyte response database 16, systems of this invention may be used to analyze data in database 16. For example, it may be desirable to extract all leukocyte response data for a particular concentration of a particular drug. Referring to FIG. 3, the steps required to provide such a leukocyte response profile are described.
- the system receives information from a user who may interact directly with the computer, or may interact with the computer via the Internet.
- the system requests the drug name and concentration.
- the system scans leukocyte response data from database 16 to determine if any data match the request.
- the system determines if any data match the user's request. If no data match, the system at step 40 reports to the user that no data match the request. If database 16 contains matching data, the system at step 42 displays the leukocyte response profile for the user.
- FIG. 4A An illustrative display of a leukocyte response profile is shown in FIG. 4A.
- Display 44 shows the response of a subpopulation of leukocytes 50 (e.g. B-cells, T-cells, monocytes, platelets, dendritic cells and basophils) to concentration 48 (e.g., 25 ⁇ M) of drug 46 (e.g., cyclosporin A) .
- Display region 52 shows activators used for each cell type, and display region 50 shows the response of cell activation markers for each cell type.
- Display 44 may be a multicolor display, with different colors indicating response suppression or enhancement, as indicated by legend 56.
- the response of TNF ⁇ in monocytes is enhanced to approximately 155-180% compared to a baseline response (i.e., in the absence of any drug).
- Systems of this invention may perform other analyses of data in database 16. During drug development, it may be desirable to visually compare the leukocyte responses of two different drugs.
- the system may receive information from the user as to which drugs and which cell types to display, and then may display the leukocyte response profiles for the drugs.
- FIG. 4B shows leukocyte response data for two different drugs: herbimycin (upper trace) and cyclosporin A (lower trace) .
- the system at step 60 receives leukocyte response data for the unknown drug from a user.
- the system searches database 16 to match leukocyte response profiles for the unknown drug with leukocyte response profiles for known drugs in the database.
- the system may use any of a number of previously known estimation techniques, such as minimum least-squares error techniques, or other suitable techniques.
- the system displays the results to the user.
- the system may display a result indicating that compound "X" has a leukocyte response profile that most closely matches the leukocyte response profile of penicillin. From this result, the user may conclude that compound "X” may have other pharmacologic properties that are similar to those of penicillin. Thus, if it is known that a given concentration of penicillin in whole blood is toxic, the user may conclude from the analysis that a similar concentration of compound "X" in whole blood also may be toxic.
- Systems of this invention also may be used for drug characterization and stratification of the patient population.
- the leukocyte response profile for a particular concentration of a particular drug by patients who share a particular characteristic or genetic profile may be distinct from the response of patients who lack the characteristic or genetic profile.
- patients with high blood pressure may have a leukocyte response profile for herbimycin that distinctively differs from the response profile of patients with normal blood pressure.
- Leukocyte response records in leukocyte response database 16 may include such additional characteristics, and the system of the present invention may be used to identify these common characteristics .
- a leukocyte response record 66 of this invention may include the same fields as record 20 shown in FIG. 2, but also may include three additional fields 68, 70 and 72 that may be used to include additional characteristics about individual patients. For example, fields 68, 70 and 72 may be used to indicate that the patient is male, overweight, and hypoglycemic, respectively.
- the system at step 74 receives individual screening factors from the user. For example, the user may request that the system sort the data in database 16 based on whether the patient is hypoglycemic.
- the system sorts the data, averages the leukocyte response data from all patients who are hypoglycemic, and separately averages the leukocyte response data from all patients who are non- hypoglycemic.
- the system displays the results to the user. FIG.
- FIG. 8 illustrates an exemplary display of such a search, which indicates that in hypoglycemic patients, a concentration of 25 ⁇ M of drug "Y” boosted the expression of IL-2 in T-cells.
- Systems in accordance with this invention also may be used to integrate leukocyte response data with data contained in other scientific and in-house databases to provide additional information useful for drug development.
- the system displays the leukocyte response profile for drug "Z,” which has a certain desirable response.
- the leukocyte response profile may indicate that 10 ⁇ M of drug "Z” boosts T-cell activation. Nevertheless, the researcher may be uncertain about some other characteristic of drug "Z,” such as the drug's bioavailability.
- the system may provide links to other databases that may provide such information, such as a structure activity relationship (SAR) database that contains additional information about drug "Z” or its chemical constituents.
- SAR structure activity relationship
- the researcher may discover that the bioavailability of drug "Z” is unacceptably low, but may recognize through links and other query tools that by modifying the structure of drug "Z," the bioavailability may be increased.
- the system may then synthesize the modified drug (e.g., drug "Z'"), and determine that the bioavailability of drug "Z”' in fact is higher than that of drug "Z.” The researcher preferably also would determine whether drug "Z'” shares the same desirable leukocyte response profile as drug “Z.”
- the system receives leukocyte response data for drug "Z'” from the user, and at step 86, the system compares the leukocyte response profiles of drug "Z”' with drug “Z.”
- the system displays the result to the user. If the leukocyte response profile for drug "Z'” is unacceptable, the user may wish to evaluate other synthesized drugs (e.g., drug "Z''”). Accordingly, at step 90, the system may ask whether the user wants to evaluate the leukocyte response profile of other drugs. If YES, the system repeats steps 84-90. If NO, the system may provide other options at step 92.
- Systems in accordance with this invention also may be used to assist genetic research by integrating leukocyte response data with data contained in genetic databases.
- links to genetic databases similarly indexed may permit the identification of correlations between lymphocyte response profiles and expression data for other types of genes, or may permit the identification of correlations of lymphocyte response profiles with SNPs, presence or absence of microsatellite repeats, identifiable RFLPs, or other detectable genetic sequence variation.
- the system of the present invention also may be used to learn how drugs affect the immune response. For example, a researcher may know that particular concentrations of four different drugs each suppress the leukocyte response, and may hypothesize that the drugs' activity affects a particular signal transduction intermediate common to one or more activation markers for one or more leukocyte cell types. If the leukocyte response record for database 16 includes an additional field for signal transduction intermediates (e.g., NF- ⁇ B) , the system of the present invention may provide information that is used to confirm or disprove the hypothesis. Referring to FIG. 10, the system at step 94 first receives information from the user (e.g., sort data for four drugs based on signal transduction element NF- ⁇ B) .
- information from the user e.g., sort data for four drugs based on signal transduction element NF- ⁇ B
- FIG. 11 illustrates an exemplary display, which shows that each of the four drugs affects NF- ⁇ B-dependent signal transduction pathways differently, and thus confirms the hypothesis.
- FIG. 12 depicts an illustrative computer system and network on which systems of the present invention may be implemented.
- Internet server 100 comprises a computer connected to the Internet via a high-speed connection, and is also connected to LAN 102.
- Internet server 100 preferably runs a standard HTTP server application, such as Apache, which is available for free from the Apache organization at "http://www.apache.org".
- Internet server 100 accepts HTTP connections from computers on the Internet, and sends web pages across the Internet to client computers, such as client computer 104.
- Internet server 100 also runs a variety of scripts (such as Java "servlets” or CGI scripts) to interact with users across the Internet, to dynamically build web pages, and to access data stored on database server 106. Most of the routines for interacting with a user, and for analyzing data in database 16 are stored and executed on Internet server 100.
- Database server 106 comprises a computer system connected to LAN 102 that provides access to database 16, which is stored on RAID array 110.
- Database server 106 executes database software that permits other computers to access database 16 over LAN 102.
- LAN 102 also may be connected to additional computers 108, that may be used, for example, to enter leukocyte response data into database 16. Most of the functions that are performed using computers 108 connected to LAN 102 also may be performed over the Internet.
- Client computer 104 executes standard Internet browser software, such as Netscape Navigator, by Netscape Communications Corporation, of Mountain View, California.
- Client computer 104 uses the browser software to interact with Internet server 100 across the Internet, and to display web pages provided by Internet server 100 to the user.
- Input forms generated by the system of the present invention, as well as the displays generated by the system are displayed to the user by the browser software running on client computer 104.
- database server 106 may be combined with Internet server 100.
- database 16 may be stored on a normal hard drive or other magnetic media, an optical disk, or in a distributed fashion on computers 108 on LAN 102, rather than on RAID array 110.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71291/00A AU7129100A (en) | 1999-09-10 | 2000-09-08 | Apparatus and methods for drug analysis and development |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15333499P | 1999-09-10 | 1999-09-10 | |
US60/153,334 | 1999-09-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001018735A2 true WO2001018735A2 (en) | 2001-03-15 |
WO2001018735A3 WO2001018735A3 (en) | 2002-02-07 |
WO2001018735B1 WO2001018735B1 (en) | 2002-06-20 |
Family
ID=22546762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/024781 WO2001018735A2 (en) | 1999-09-10 | 2000-09-08 | Apparatus and methods for drug analysis and development |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7129100A (en) |
WO (1) | WO2001018735A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001093113A1 (en) * | 2000-03-28 | 2001-12-06 | Dana-Farber Cancer Institute, Inc. | Molecular database for antibody characterization |
WO2002088383A2 (en) * | 2001-04-27 | 2002-11-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0316861B1 (en) * | 1987-11-16 | 1995-06-28 | Becton, Dickinson and Company | Hematology-diagnosis apparatus employing expert system technology |
US5639623A (en) * | 1989-09-08 | 1997-06-17 | Yamauchi; Tamio | Method of measuring immunokinetics |
US5899998A (en) * | 1995-08-31 | 1999-05-04 | Medcard Systems, Inc. | Method and system for maintaining and updating computerized medical records |
WO1999036564A1 (en) * | 1998-01-16 | 1999-07-22 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US5930791A (en) * | 1996-12-09 | 1999-07-27 | Leu; Sean | Computerized blood analyzer system for storing and retrieving blood sample test results from symmetrical type databases |
-
2000
- 2000-09-08 WO PCT/US2000/024781 patent/WO2001018735A2/en active Application Filing
- 2000-09-08 AU AU71291/00A patent/AU7129100A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0316861B1 (en) * | 1987-11-16 | 1995-06-28 | Becton, Dickinson and Company | Hematology-diagnosis apparatus employing expert system technology |
US5639623A (en) * | 1989-09-08 | 1997-06-17 | Yamauchi; Tamio | Method of measuring immunokinetics |
US5899998A (en) * | 1995-08-31 | 1999-05-04 | Medcard Systems, Inc. | Method and system for maintaining and updating computerized medical records |
US5930791A (en) * | 1996-12-09 | 1999-07-27 | Leu; Sean | Computerized blood analyzer system for storing and retrieving blood sample test results from symmetrical type databases |
WO1999036564A1 (en) * | 1998-01-16 | 1999-07-22 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001093113A1 (en) * | 2000-03-28 | 2001-12-06 | Dana-Farber Cancer Institute, Inc. | Molecular database for antibody characterization |
US7058658B2 (en) | 2000-03-28 | 2006-06-06 | Dana-Farber Cancer Institute, Inc. | Molecular database for antibody characterization |
WO2002088383A2 (en) * | 2001-04-27 | 2002-11-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
WO2002088383A3 (en) * | 2001-04-27 | 2003-10-09 | Max Planck Gesellschaft | Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU7129100A (en) | 2001-04-10 |
WO2001018735B1 (en) | 2002-06-20 |
WO2001018735A3 (en) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7555492B2 (en) | System and method for internet-accessible tools and knowledge base for protocol design, metadata capture and laboratory experiment management | |
US6947953B2 (en) | Internet-linked system for directory protocol based data storage, retrieval and analysis | |
Robinette et al. | Statistical spectroscopic tools for biomarker discovery and systems medicine | |
Iyer et al. | CyTOF® for the Masses | |
Herold et al. | Immunoassays for testosterone in women: better than a guess? | |
Shaw et al. | Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring | |
Duffy et al. | Early phase drug discovery: cheminformatics and computational techniques in identifying lead series | |
Swanson et al. | Ranking indirect connections in literature‐based discovery: The role of medical subject headings | |
De Souza et al. | Progressive peak clustering in GC-MS Metabolomic experiments applied to Leishmania parasites | |
JP5649874B2 (en) | Method and system for validating changes in medical practices, techniques, and product selection | |
Spidlen et al. | GenePattern flow cytometry suite | |
Nogimori et al. | OMIP 078: A 31‐parameter panel for comprehensive immunophenotyping of multiple immune cells in human peripheral blood mononuclear cells | |
Yang et al. | Guidelines for standardizing T‐cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes | |
JP7440872B2 (en) | Analysis equipment and analysis method | |
WO2001018735A2 (en) | Apparatus and methods for drug analysis and development | |
Tsai et al. | High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis | |
Arend et al. | A systematic comparison of novel and existing differential analysis methods for CyTOF data | |
WO2014145234A2 (en) | Systems and apparatus for integrated and comprehensive biomedical annotation of bioassay data | |
Catlin | Urine testing: A comparison of five current methods for detecting morphine | |
Preglej et al. | Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach | |
Dechert et al. | Multivariate approach to quality control in clinical chemistry | |
Fostel et al. | Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis | |
Minović et al. | Interpretation of folate results in hemolytic plasma samples: a practical approach | |
JP2022182568A (en) | Document retrieval support device | |
Camp et al. | Deep neural network for cell type differentiation in myelodysplastic syndrome diagnosis performs similarly when trained on compensated or uncompensated data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |